Cancer and Metastasis Reviews

, Volume 29, Issue 2, pp 339–350

Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal

  • Andrea Tinelli
  • Antonio Malvasi
  • Giuseppe Leo
  • Daniele Vergara
  • Maurizio Pisanò
  • Mariangela Ciccarese
  • Vincenzo Emanuele Chiuri
  • Vito Lorusso
NON-THEMATIC REVIEW

DOI: 10.1007/s10555-010-9218-3

Cite this article as:
Tinelli, A., Malvasi, A., Leo, G. et al. Cancer Metastasis Rev (2010) 29: 339. doi:10.1007/s10555-010-9218-3

Abstract

In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.

Keywords

Hereditary ovarian cancerBRCAProphylactic surgeryGeneticsGenetic testingHNPCCLaparoscopyOophorectomyCounselingRisk assessment

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Andrea Tinelli
    • 1
    • 6
  • Antonio Malvasi
    • 2
  • Giuseppe Leo
    • 3
  • Daniele Vergara
    • 4
  • Maurizio Pisanò
    • 3
  • Mariangela Ciccarese
    • 5
  • Vincenzo Emanuele Chiuri
    • 5
  • Vito Lorusso
    • 5
  1. 1.Department of Gynaecology and ObstetricsVito Fazzi HospitalLecceItaly
  2. 2.Department of Gynaecology and ObstetricsSanta Maria HospitalBariItaly
  3. 3.Molecular Biology and Experimental Oncology LabVito Fazzi HospitalLecceItaly
  4. 4.Laboratory of Biology, Department of Biological and Environmental Sciences and Technologies (DiSTeBA)University of SalentoLecceItaly
  5. 5.Department of Clinical OncologyVito Fazzi HospitalLecceItaly
  6. 6.Department of Gynecology and Obstetric, Division of Experimental Endoscopic Surgery, Imaging, Minimally Invasive TherapyVito Fazzi HospitalLecceItaly